Robert Richard Flavell MD PhD
Fellow, Nuclear Medicine, University of California, San Francisco
Join to View Full Profile
505 Parnassus AveBox 0628New York, NY 94143
Dr. Flavell is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of California (San Francisco)Fellowship, Nuclear Medicine, 2016- University of California (San Francisco)Residency, Radiology-Diagnostic, 2011 - 2015
Memorial Sloan Kettering Cancer CenterInternship, Transitional Year, 2010 - 2011
Weill Cornell MedicineClass of 2010
Rockefeller UniversityPhD, Chemical Biology, 2004 - 2009
Certifications & Licensure
CA State Medical License 2011 - 2025
American Board of Nuclear Medicine Nuclear Medicine
American Board of Radiology Diagnostic Radiology
Clinical Trials
- [18F]FAraG PET Imaging for Analysis of Biodistribution in Cancer Patients Expected to Undergo Immunotherapy and/or Radiation Therapy Start of enrollment: 2017 May 01
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostat...Rahul R Aggarwal, Jacqueline Vuky, David VanderWeele, Matthew Rettig, Elisabeth I Heath
Journal of Clinical Oncology. 2025-03-26 - Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac Therapy.Anil P Bidkar, Robin Peter, Anju Wadhwa, Kondapa Naidu Bobba, Scott Bidlingmaier
Clinical Cancer Research. 2025-02-13 - Millimeter-scale radioluminescent power for electronic sensors.Averal N Kandala, Sinan Wang, Joseph E Blecha, Yung-Hua Wang, Rahul K Lall
Iscience. 2025-01-17
Journal Articles
- First-in-Human Phase I Study of CTT1057, a Novel 18F Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate Specific Membrane Antigen in Prostate CancerSpencer C Behr, Hao G Nguyen, Thomas A Hope, Kirsten L Greene, Matthew R Cooperberg, Robert R Flavell, Eric J Small, Peter R Carroll, Journal of Nuclear Medicine
Press Mentions
Shuttle Enters Agreement with UCSF to Develop PSMA LigandDecember 19th, 2024
First-of-Its-Kind Study Demonstrates Clinical Impact of Amyloid PET ImagingApril 3rd, 2019- Conference Convenes Experts in the Field of Nuclear Medicine to Advance Prostate Cancer CareJanuary 26th, 2024
Grant Support
- Selective treatment of acute myeloid leukemia with radioimmunotherapies targeting the active conformation of integrin beta-2UNIVERSITY OF CALIFORNIA, SAN FRANCISCO2025–2030
- Systematic evaluation of toxicity and therapeutic efficacy in CD46 directed radioligand therapyUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2023–2028
- Development of CD46 theranostics for imaging and treatment of multiple myelomaUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2022–2027
- Molecular imaging of novel PARP inhibitor nanomedicine deliveryUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2022–2026
- ACE2-targeted PET radiotracers for investigating spatiotemporal distribution of SARS-CoV-2 organ injury and therapy response.UNIVERSITY OF CALIFORNIA, SAN FRANCISCO2021–2025
- Mitzi and William Blahd, MD Pilot Research GrantEducation and Research Foundation for Nuclear Medicine and Molecular Imaging2015–2016
- Research fellow grantRadiological Society of North America2015–2016
- T32NIH2014–2015
Committees
- Intern, Society of Nuclear Medicine, Clinical Trials Network 2015 - Present
Research History
- T32 Research Resident2014 - 2015
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
